Drug Deal Disclosure Act
Key claim: The Drug Deal Disclosure Act (HR9699, 119th Congress) was referred to the Committees on Energy and Commerce, Ways and Means, and the Budget, indicating proposed disclosure requirements related to pharmaceutical drug deals or pricing.
Abstract
(HR9699 · 119th Congress) Latest action (2026-07-15): Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and the Budget, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Why this matters
Drug-deal disclosure legislation would add another transparency layer to the federal pharmaceutical pricing regime, potentially requiring manufacturers, PBMs, or intermediaries to report deal terms that today are shielded as confidential. At introduction the bill is a title-and-referral only, so its practical effect on patient out-of-pocket costs, payer negotiations, or FDA/CMS oversight cannot yet be assessed.